<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koch Chaves, H.</style></author><author><style face="normal" font="default" size="100%">de Freitas da Silveira, C. C.</style></author><author><style face="normal" font="default" size="100%">de Souza Antunes, A. M.</style></author><author><style face="normal" font="default" size="100%">Lima de Magalhães, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">AN OVERVIEW OF SCIENTIFIC PRODUCTION ON INJECTABLE ANTINEOPLASTICS IN THE WEB OF SCIENCE DATABASE AS A CONTRIBUTION TO PUBLIC HEALTH MANAGEMENT</style></title><secondary-title><style face="normal" font="default" size="100%">Problems of Management in the 21st Century</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">bibliometric analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">co-citation</style></keyword><keyword><style  face="normal" font="default" size="100%">injectable antineoplastics</style></keyword><keyword><style  face="normal" font="default" size="100%">public health</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December/2023</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://oaji.net/articles/2023/450-1705396590.pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">Continuous</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">According to data from the United Nations, cancer is the second leading cause of death in the world. Studies in the area advocate that this data be treated in an agile manner, to extract essential information. This work analyzed the characteristics of the world's scientific production on injectable oncologic agents present in articles in the Web of Science database between 2001 and 2021. Bibliometrics were performed on 1,496 articles. There was a constant increase in publications over the years – emphasis on 2021. The technological domain “pharmacy and pharmacology” was the most recurrent. China is the leader with a total of 505, while Elsevier was the publisher of the most published articles in the analyzed period. In relation to the most productive authors, Qian ZY stands out, with 18 articles. The most productive institution is the Chinese Academy of Sciences with 68 articles. Concerning networks using VOSviewer®, the following stand out: Li, Y. et al. (2012), (co-citation of references; 62); “Biomaterials” (co-citation of journals; 3,006); nanoparticles (keyword co-occurrence; 262); Soo-Chang Song (bibliographic coupling; 776). The study helps public health stakeholders in injectable antineoplastics to obtain essential information and thus contribute to better health management in both the public and private sectors.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original article</style></work-type><section><style face="normal" font="default" size="100%">21-33</style></section></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lima de Magalhães, J.</style></author><author><style face="normal" font="default" size="100%">Luc   Quoniam</style></author><author><style face="normal" font="default" size="100%">Núbia   Boechat</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">PHARMACEUTICAL MARKET AND OPPORTUNITY IN THE 21ST CENTURY FOR GENERIC DRUGS: A BRAZILIAN CASE STUDY OF OLANZAPINE</style></title><secondary-title><style face="normal" font="default" size="100%">Problems of Management in the 21st Century</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">competitive intelligence</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmaceutical trends</style></keyword><keyword><style  face="normal" font="default" size="100%">technological and innovation management</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April/2013</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://oaji.net/articles/2014/450-1392545960.pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">6</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">This paper aimed to identify and analyse the evolution of the generic pharmaceutical market in Brazil, specifically olanzapine drugs. For this purpose, it has been demonstrated trends through access free tools. By bibliographical survey in indexed databases as well as official data in Brazil for generic drugs and public policy, it was analyzed and performed a case study . In 2012, global pharmaceutical industry surpassed US$ 950 billion in sales with trend to reach US$ 1,2 trillion by 2016. In Brazil market has grown in its global ranking, jumped from 10th place to 7th place in five years and projection it’ll stay Top five by 2015. Brazil has significant presence in pharmerging markets by increasing US$ 10 billion/year. Generics segment accounts approximately to 20% of the total market. 2003-2011 registered a growth of 42.3%. Patents expiration in the neuroleptics area becomes more promising like a market of olanzapine in the last eight years is around US$ 120 million. After the end of the olanzapine patent (2011) sales increased 270% which demonstrate potential Brazilian market in this new century. Management problems for developing nations and undeveloped such as network management and patents analysis for health care might reveal great opportunities for investors, e.g., creation of the Big Brazilian biotechnology pharmaceutical industry.</style></abstract><work-type><style face="normal" font="default" size="100%">Original article</style></work-type><section><style face="normal" font="default" size="100%">31-39</style></section></record></records></xml>